Evidence map›Paper›PMID 39756006›Full record

ArticleAngiogenesis2025

Ref-1 is overexpressed in neovascular eye disease and targetable with a novel inhibitor.

Anbukkarasi Muniyandi, Gabriella D Hartman, Kamakshi Sishtla, Ratan Rai, Cátia Gomes, Kristina Day, Yang Song, Andi R Masters, Sara K Quinney, Xiaoping Qi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angiogenesis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Ref-1 redox activity regulates retinal neovascularization by modulating transcriptional activation of HIF-1α.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Anbukkarasi MuniyandiDepartment of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA.
Gabriella D HartmanDepartment of Ophthalmology, Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
Kamakshi SishtlaDepartment of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA.
Ratan RaiDepartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Cátia GomesStark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
Kristina DayDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Yang SongDepartment of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA.
Andi R MastersDivision of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA.
Sara K QuinneyDivision of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA.
Xiaoping QiDepartment of Ophthalmology and Visual Sciences, University of Alabama at Birmingham, Birmingham, AL, USA.
Hailey WoodsDepartment of Biology, Indiana University-Purdue University Indianapolis, Indianapolis, IN, USA.
Michael E BoultonDepartment of Ophthalmology and Visual Sciences, University of Alabama at Birmingham, Birmingham, AL, USA.
Jason S MeyerDepartment of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA.
Jonah Z VilseckDepartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Millie M GeorgiadisDepartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Mark R KelleyDepartment of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA.
Timothy W CorsonDepartment of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA. tim.corson@utoronto.ca.

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI David W Clapp · 1999 to 2026
$59.3M
Novel Role of Ref-1 in Pancreatic Cancer Etiology and ProgressionR01CA167291 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI FISHEL, MELISSA L., KELLEY, MARK R. · 2013 to 2022
$5.2M
Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor MicroenvironmentU01CA274304 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Melissa L. Fishel, Matthew J. Flick · 2022 to 2026
$4.6M
Hyperglycemia mediated myeloproliferative diseaseR01HL140961 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI KAPUR, REUBEN · 2019 to 2022
$2.3M
Investigation of novel signaling protein in 3D and in vivo PDAC models using second generation Ref-1 inhibitorsR01CA254110 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI FISHEL, MELISSA L., HAN, BUMSOO · 2021 to 2025
$2.1M
Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancerR01CA282478 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI Melissa L. Fishel, Mark R. Kelley · 2023 to 2026
$2.1M
Tackling Multifaceted Drug Design Problems with Lambda Dynamics Based TechnologiesR35GM146888 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI JONAH VILSECK · 2022 to 2026
$1.9M
Targeting the Ref-1 signaling node for treating ocular neovascularizationR01EY031939 · NEI · INDIANA UNIVERSITY INDIANAPOLIS · PI CORSON, TIMOTHY W, KELLEY, MARK R. · 2020 to 2023
$1.7M
Ref-1 in Retinal NeovascularizationF31EY035171 · NEI · INDIANA UNIVERSITY INDIANAPOLIS · PI HARTMAN, GABRIELLA · 2023 to 2024
$69k
NCI NIH HHS P30 CA082709NCI NIH HHS P30CA082709NCI NIH HHS R01 CA167291NCI NIH HHS R01 CA254110NCI NIH HHS R01 CA282478NCI NIH HHS U01 CA274304NEI NIH HHS F31 EY035171NEI NIH HHS F31EY035171NEI NIH HHS R01 EY031939NEI NIH HHS R01EY031939NHLBI NIH HHS R01 HL140961NHLBI NIH HHS R01HL140961NIGMS NIH HHS R35 GM146888
6 · The paper itself

Abstract

Reduction-oxidation factor-1 or apurinic/apyrimidinic endonuclease 1 (Ref-1/APE1) is a crucial redox-sensitive activator of transcription factors such as NF-κB, HIF-1α, STAT-3 and others. It could contribute to key features of ocular neovascularization including inflammation and angiogenesis; these underlie diseases like neovascular age-related macular degeneration (nAMD). We previously revealed a role for Ref-1 in the growth of ocular endothelial cells and in choroidal neovascularization (CNV). Here, we set out to further explore Ref-1 in neovascular eye disease. Ref-1 was highly expressed in human nAMD, murine laser-induced CNV and Vldlr

Indexed as

Choroidal NeovascularizationDNA-(Apurinic or Apyrimidinic Site) LyaseAnimalsDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLMice, KnockoutReceptors, LDLApex1 protein, mouseDNA-(Apurinic or Apyrimidinic Site) LyaseReceptors, LDLVLDL receptorAngiogenesisHypoxiaInflammationNeovascular age-related macular degenerationRedox signalingReduction–oxidation factor-1

Identifiers

PMID39756006
PMCPMC12019292

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.